Pull the syringe to:
(0.100ml)
Concentration: 5.00 mg/ml
Doses per vial: 30
This calculator is provided as a reference tool for research purposes only. Always follow your institution’s safety protocols when handling research compounds.
KLOW Peptide Blend 80mg is a research-use peptide blend listed for laboratory work involving cellular signalling, tissue-response pathway models, inflammatory pathway research, peptide interaction research and cellular pathway studies.
Because blend products can vary by supplier, the exact component peptides, component amounts, blend ratio, salt forms and purity results must be confirmed through the product label and Certificate of Analysis before laboratory use.
This page does not assume the blend contains any specific peptides unless confirmed by supplier documentation. If the Certificate of Analysis confirms components such as KPV, BPC-157, TB-500, GHK-Cu, ARA-290 or other peptides, those ingredients should be added to the component table and concentration planning sections with their exact confirmed amounts.
| Product Detail | Information |
|---|---|
| Product name | KLOW Peptide Blend |
| Size | 80mg |
| Product type | Research peptide blend |
| Research category | Tissue Response Research / Cellular Signalling Research / Peptide Interaction Research |
| Common research interest | Cellular signalling, tissue-response models, inflammatory pathway research and peptide interaction studies |
| Blend format | Multi-component research peptide preparation |
| Component ratio | Must be confirmed by product label and Certificate of Analysis |
| Stock status | Listed as in stock in the product SEO sheet |
| Form | Lyophilised powder or supplier-specific research preparation |
| Intended use | Laboratory research only |
| Human use | Not for human consumption, administration, inflammation, tissue repair, recovery, wound healing or injection |
| Documentation | Certificate of Analysis should be checked before use |
Important: Do not assume the KLOW Peptide Blend 80mg vial contains equal parts of each component. The total 80mg amount, exact ingredient list and component ratio must be confirmed through the product label and Certificate of Analysis.
| Component | Research Class | General Research Role |
| KLOW Peptide Blend | Multi-peptide research preparation | Studied as a blend in cellular signalling, inflammatory pathway and tissue-response pathway research models |
| Component 1 | CoA-dependent | Confirm through supplier documentation |
| Component 2 | CoA-dependent | Confirm through supplier documentation |
| Component 3 | CoA-dependent | Confirm through supplier documentation |
| Component 4 | CoA-dependent | Confirm through supplier documentation if applicable |
| Total blend amount | 80mg | Used for total blend concentration planning |
| Individual component amounts | CoA-dependent | Required for component-specific concentration calculations |
| Salt forms or counter-ions | CoA-dependent | May affect calculations, solubility and handling |
| Lyophilised preparation | Freeze-dried research format | Supports storage before laboratory preparation when stored correctly |
A blend should never be treated as a verified combination of known peptides unless the Certificate of Analysis confirms the identity and amount of each component.
Some tissue-response peptide blends in the broader research peptide space may use ingredients such as KPV, BPC-157, TB-500, GHK-Cu or ARA-290. These should only be mentioned as confirmed components on the product page if the KLOW Peptide Blend 80mg Certificate of Analysis confirms they are actually present.
If confirmed:
| Possible Component | Safer Research Positioning |
| KPV | Alpha-MSH-derived inflammatory pathway and cellular signalling research |
| BPC-157 | Stable gastric pentadecapeptide and cytoprotection pathway research |
| TB-500 | Thymosin beta-4 fragment, actin and cell migration pathway research |
| GHK-Cu | Copper peptide, extracellular matrix and cellular pathway research |
| ARA-290 / Cibinetide | Innate repair receptor and small nerve fibre pathway research |
The TGA has specifically named BPC-157, GHK-Cu and TB-500 among examples of unapproved peptide products that can raise public health and regulatory risks when promoted or supplied for human use.
KLOW Peptide Blend 80mg is best positioned as a multi-component research blend for cellular pathway, inflammatory pathway, peptide interaction and tissue-response research models. Its exact research mechanism depends on the confirmed peptide components and their ratio.
Where a blend contains multiple peptides, the research framing should focus on component verification, interaction models, batch documentation, concentration planning and laboratory handling. It should not be written as if the blend has proven human benefits, stronger effects, faster outcomes or greater biological activity than individual peptides.
Because the name “KLOW” may not clearly identify the ingredients, product copy should avoid assuming it contains KPV, GHK-Cu, BPC-157, TB-500 or any other peptide unless the CoA confirms the exact composition.
| Research Area | KLOW Peptide Blend 80mg |
| Main research category | Cellular signalling and tissue-response research |
| Product type | Multi-component research peptide blend |
| Component identity | Must be confirmed by CoA |
| Component ratio | Must be confirmed by CoA |
| Common pathway interest | Cellular signalling, inflammatory pathway models and peptide interaction research |
| Blend-specific requirement | Total and component concentrations must be calculated separately |
| Common compliance risk | Anti-inflammatory, tissue repair, wound-healing, recovery and injection claims |
| Product limitation | Research use only, not approved for human or animal use |
| Feature | KLOW Peptide Blend 80mg | KPV |
| Product type | Multi-component research blend | Single tripeptide research peptide |
| Component identity | CoA-dependent | Lys-Pro-Val peptide sequence |
| Research focus | Cellular signalling, tissue-response and peptide interaction models | Inflammatory pathway and melanocortin-related research |
| Concentration planning | Total blend and component-specific calculations | Single-peptide concentration calculations |
| Common SEO risk | Inflammation, healing and tissue repair claims | Gut health, anti-inflammatory and autoimmune claims |
| Safer positioning | CoA-confirmed peptide blend research | KPV inflammatory pathway research |
| Feature | KLOW Peptide Blend 80mg | GLOW Peptide Blend 50mg / 70mg |
| Product type | Multi-component research blend | Multi-component research blend |
| Total amount | 80mg | 50mg or 70mg |
| Component identity | Must be confirmed by CoA | Must be confirmed by CoA |
| Research positioning | Cellular signalling, inflammatory pathway and tissue-response research | Cellular signalling, extracellular matrix and tissue-response research |
| Main copy risk | Inflammation, tissue repair and recovery claims | Cosmetic, glowing skin and anti-ageing claims |
| Safer positioning | CoA-confirmed tissue-response blend research | CoA-confirmed cellular pathway blend research |
| Feature | KLOW Peptide Blend 80mg | BPC-157 + TB-500 10mg |
| Product type | Multi-component research blend | Two-component research peptide blend |
| Component certainty | Must be confirmed by CoA | BPC-157 and TB-500 named in product title |
| Total amount | 80mg | 10mg |
| Research positioning | Cellular signalling, inflammatory pathway and blend interaction research | Gastric pentadecapeptide and thymosin beta-4 fragment pathway research |
| Main copy risk | Anti-inflammatory, recovery and tissue repair claims | Injury recovery and sports recovery claims |
| Safer positioning | CoA-confirmed peptide blend research | Dual-component pathway research |
| Product | Safer Research Positioning |
| KLOW Peptide Blend 80mg | CoA-confirmed cellular signalling, inflammatory pathway and tissue-response research blend |
| GLOW Peptide Blend 50mg | CoA-confirmed cellular signalling and extracellular matrix research blend |
| GLOW Peptide Blend 70mg | Higher-strength CoA-confirmed cellular pathway research blend |
| BPC-157 + TB-500 10mg | Dual-component gastric pentadecapeptide and thymosin beta-4 fragment research blend |
| KPV 10mg | Alpha-MSH-derived inflammatory pathway research |
| ARA-290 Cibinetide 10mg | Innate repair receptor and small nerve fibre pathway research |
| GHK-Cu 50mg / 100mg | Copper peptide and extracellular matrix pathway research |
| TB-500 10mg | Thymosin beta-4 fragment, actin and cell migration pathway research |
These products should not be written as if they are interchangeable. KLOW Peptide Blend 80mg should be positioned as a CoA-confirmed research blend only, not as a human inflammation, healing, pain relief, tissue repair or recovery product.
| Common Online Claim | Safer Research-Use Wording |
| Anti-inflammatory support | Studied in inflammatory pathway research models |
| Tissue repair | Better framed as tissue-response pathway research |
| Wound healing | Better framed as wound-response research models only |
| Injury recovery | Not an approved or appropriate product claim |
| Pain relief | Not an approved or appropriate product claim |
| Gut support | Better framed as barrier or cellular pathway research if a confirmed component supports it |
| Immune support | Better framed as cytokine or inflammatory signalling research |
| Recovery | Not suitable for research-use product positioning |
| Skin repair | Better framed as cellular and extracellular matrix research only if supported by confirmed components |
| Injectable blend | Not suitable for research-use product positioning |
KLOW Peptide Blend 80mg is not intended to diagnose, treat, cure or prevent any disease. It is not supplied for inflammation, pain relief, immune support, gut health, tissue repair, wound healing, injury recovery, skin repair, recovery, cosmetic use, topical use, injection, supplementation or therapeutic use.
All information on this page is provided for laboratory research and product handling context only.
There is no universal recommended dilution for KLOW Peptide Blend 80mg. Dilution depends on the research protocol, required working concentration, assay design, solvent compatibility, component ratio, salt forms, pH conditions, storage method and validated laboratory procedure.
For research concentration planning only, the basic formula is:
Total blend amount divided by diluent volume equals final total blend concentration.
If the product documentation confirms individual peptide amounts, each component concentration should be calculated separately from its confirmed amount.
| Diluent Added to 80mg Total Blend | Final Total Blend Concentration |
| 1mL | 80mg/mL |
| 2mL | 40mg/mL |
| 4mL | 20mg/mL |
| 5mL | 16mg/mL |
| 8mL | 10mg/mL |
| 10mL | 8mg/mL |
| 16mL | 5mg/mL |
| 20mL | 4mg/mL |
| 40mL | 2mg/mL |
| 80mL | 1mg/mL |
These are research concentration examples only. They are not human dosing instructions and must not be used to calculate injection quantities, treatment quantities, topical quantities or administration schedules.
Use this table only after the product label and Certificate of Analysis confirm each component and amount.
| Confirmed Component | Amount in 80mg Blend | Diluent Volume | Component Concentration |
| Component 1 | Confirm by CoA | 10mL | Amount ÷ 10mL |
| Component 2 | Confirm by CoA | 10mL | Amount ÷ 10mL |
| Component 3 | Confirm by CoA | 10mL | Amount ÷ 10mL |
| Component 4 | Confirm by CoA, if applicable | 10mL | Amount ÷ 10mL |
| Total blend | 80mg | 10mL | 8mg/mL |
This is a component concentration planning table only. It is not a dosing table, injection table, topical-use guide or treatment guide.
Before handling KLOW Peptide Blend 80mg in a laboratory setting, make sure all materials, documentation and clean handling conditions are prepared.
| Item | Purpose |
| Product vial | Contains lyophilised KLOW Peptide Blend |
| Certificate of Analysis | Confirms batch-level testing information |
| Component identity confirmation | Confirms the peptides present in the blend |
| Component ratio confirmation | Confirms the amount of each peptide |
| SDS or safety documentation | Provides handling, hazard and disposal guidance |
| Suitable research-grade diluent | Used to prepare a working research solution if compatible |
| Sterile or clean lab consumables | Helps reduce contamination risk |
| Personal protective equipment | Gloves, lab coat and eye protection |
| Alcohol wipes or approved disinfectant | Used for surface and vial-top preparation |
| Laboratory labels | Records total and component concentrations |
| Controlled storage access | Supports correct storage after preparation |
| Disposal container | Used for compliant laboratory waste disposal |
The following is a general laboratory handling framework only. Always follow the product Certificate of Analysis, supplier documentation, SDS, institutional procedures and validated research protocol.
Check the product label, batch number, Certificate of Analysis, component list, component ratio and storage requirements before handling the vial.
Use a clean laboratory workspace. Wear appropriate PPE and disinfect the bench surface, vial top and any required equipment.
Do not assume every peptide diluent is suitable for a multi-component blend. Confirm compatibility through supplier documentation, SDS and the approved research protocol.
If the vial has been stored cold, allow it to equilibrate according to laboratory procedure before opening or reconstitution. Avoid condensation entering the vial.
Add the selected research-grade diluent slowly down the inside wall of the vial. Avoid forceful spraying directly onto the lyophilised material.
Gently swirl or roll the vial until the material is dissolved. Avoid aggressive shaking, unnecessary vortexing or foaming unless a validated protocol specifically allows it.
Check the solution for unexpected cloudiness, visible particles, colour changes, precipitation or undissolved material. If anything appears abnormal, quarantine the vial and check supplier documentation.
Label the vial or aliquots with the product name, total concentration, component concentrations where confirmed, diluent used, date prepared, batch number and researcher initials. Store according to the validated protocol as soon as possible.
Some peptide blends may require protocol-specific handling. Dissolution should always be handled gently and according to laboratory documentation.
| Issue | What It May Indicate | Safer Response |
| Powder clinging to vial wall | Static or lyophilisation residue | Allow more contact time with diluent |
| Small particles remain | Incomplete hydration or concentration issue | Continue gentle mixing and check protocol |
| Cloudy solution | Possible incompatibility or contamination | Stop and check documentation |
| Precipitation appears | Possible pH, solvent, concentration or component incompatibility | Quarantine and reassess preparation method |
| Unexpected colour change | Possible degradation, oxidation or contamination | Do not continue without supplier guidance |
| Component identity unclear | Blend documentation issue | Stop and confirm CoA before using |
| Storage Factor | Guidance |
| Product form | Lyophilised powder or supplier-specific dry preparation |
| Storage condition | Follow supplier label, CoA and SDS |
| Light exposure | Protect from unnecessary light exposure |
| Moisture exposure | Keep sealed until use |
| Temperature changes | Avoid repeated temperature cycling |
| Handling | Minimise unnecessary opening or exposure |
| Variant control | Store separately from GLOW blends and other peptide blend products |
| Component tracking | Keep the CoA accessible for ingredient and ratio verification |
| Storage Factor | Guidance |
| Storage condition | Follow validated research protocol |
| Labelling | Record product name, total concentration, component concentrations, date and batch number |
| Component tracking | Record confirmed peptide components and ratio |
| Freeze-thaw cycles | Avoid repeated freeze-thaw exposure |
| Aliquoting | Use small research aliquots where appropriate |
| Contamination control | Use clean laboratory technique |
| Light exposure | Protect from unnecessary light exposure where required |
| Disposal | Dispose according to laboratory waste procedures |
Peptide blends may be sensitive to temperature, light, pH, agitation, oxidation, solvent conditions and contamination. Storage conditions should be confirmed through supplier documentation or the laboratory’s validated method.
This page does not provide human dosing, injection instructions, injection schedules, treatment protocols, recovery protocols, topical-use directions or administration guidance.
KLOW Peptide Blend 80mg is not supplied for human or animal administration. It is a laboratory research-use product only.
For research settings, any measured aliquots should be prepared according to the concentration required by the approved research protocol. All total blend and component-specific calculations should be checked, documented and traceable.
| Planning Item | What to Record |
| Final total concentration | Total 80mg blend amount and diluent volume |
| Component concentrations | Each component amount and concentration where confirmed |
| Working solution | Concentration used in the research protocol |
| Aliquot volume | Volume transferred into each labelled lab tube |
| Batch details | Product batch, CoA and preparation date |
| Component identity | Confirmed peptide list from CoA |
| Component ratio | Confirmed amount of each peptide |
| Salt forms | Supplier-specific salt forms or counter-ions, where documented |
| Diluent or solvent | Exact diluent, solvent or vehicle used |
| Storage location | Fridge, freezer or other controlled storage area |
| Handler details | Researcher name or initials |
| Preparation date | Date and time of reconstitution |
| Disposal date | When the aliquot should no longer be used |
| Strength check | Confirmation that the 80mg blend amount matches the approved research protocol |
| Compliance check | Confirmation that no inflammation, treatment, tissue repair, recovery, topical or injection wording is attached to the material |
Correct handling is important for research consistency, contamination control, component tracking and product traceability. Most mistakes occur when blend ratios are assumed, component concentrations are not recorded, products are not labelled clearly, storage conditions are not followed or human-use claims are mixed into research-use product pages.
Because KLOW Peptide Blend may be interpreted as an inflammation, recovery or tissue-response product, product pages should avoid wording that could be interpreted as encouraging human self-use, injection, treatment use, tissue repair, wound healing, pain relief, immune support or recovery use.
| Always | Why It Matters |
| Check the Certificate of Analysis | Confirms batch-level information |
| Confirm the full component list | Prevents incorrect ingredient assumptions |
| Confirm the component ratio | Supports correct concentration planning |
| Confirm salt forms where documented | Supports accurate calculations |
| Review SDS or safety documentation | Supports safe laboratory handling and disposal |
| Use PPE | Reduces contamination and exposure risk |
| Label every vial and aliquot | Prevents mix-ups |
| Record total and component concentrations | Supports traceability |
| Use clean laboratory technique | Reduces contamination risk |
| Follow institutional protocols | Keeps handling consistent and auditable |
| Store according to documentation | Helps protect blend integrity |
| Dispose of lab waste correctly | Supports safety and compliance |
| Use research-use wording only | Reduces misleading human-use interpretation |
| Avoid treatment, recovery and anti-inflammatory claims | Keeps the page aligned with research-use positioning |
| Never | Why It Is Risky |
| Never use for self-injection | Product is research use only |
| Never sell or promote as an anti-inflammatory product | Creates human-use and therapeutic claim risk |
| Never make pain relief claims | Not an approved or appropriate product claim |
| Never make tissue-repair claims | Not suitable for a research-use product page |
| Never make wound-healing or scar-treatment claims | Not suitable for research-use material |
| Never make immune support or gut health claims | Not appropriate without regulated approval |
| Never market as injury recovery support | Creates human-use and treatment claim risk |
| Never assume the ingredient list from the name “KLOW” | Blend identity must be CoA-confirmed |
| Never assume equal component ratios | Blend ratio must be documented |
| Never assume purity without CoA | Batch quality must be documented |
| Never use a damaged or unlabelled vial | Identity and integrity may be uncertain |
| Never leave prepared solutions unlabelled | Creates traceability risk |
| Never rely on social media, clinic, recovery or human-use peptide protocols | They may be inaccurate, unsafe or non-compliant |
The table below is for concentration planning only. It does not represent dosage, injection quantity, topical-use quantity or treatment guidance.
| Total Blend Amount | Diluent Volume | Final Total Blend Concentration |
| 80mg | 1mL | 80mg/mL |
| 80mg | 2mL | 40mg/mL |
| 80mg | 4mL | 20mg/mL |
| 80mg | 5mL | 16mg/mL |
| 80mg | 8mL | 10mg/mL |
| 80mg | 10mL | 8mg/mL |
| 80mg | 16mL | 5mg/mL |
| 80mg | 20mL | 4mg/mL |
| 80mg | 40mL | 2mg/mL |
| 80mg | 80mL | 1mg/mL |
If a researcher adds 10mL of suitable research-grade diluent to an 80mg KLOW Peptide Blend vial, the resulting total blend concentration is 8mg/mL.
If the CoA confirms individual component amounts, each component concentration should be calculated separately using:
Confirmed component amount divided by diluent volume equals component concentration.
This calculation is for research concentration planning only. It is not a human or animal dosing example, treatment example, injection example, topical-use example or administration instruction.
KLOW Peptide Blend 80mg is a research-use peptide blend intended for laboratory research involving cellular signalling, tissue-response pathway models, inflammatory pathway research and peptide interaction studies.
The exact peptide components must be confirmed through the product label and Certificate of Analysis. This page should not assume the blend contains KPV, BPC-157, TB-500, GHK-Cu, ARA-290 or any other peptide unless documentation confirms it.
Not necessarily. KPV is a specific tripeptide. KLOW Peptide Blend is a blend product, and its components must be confirmed by the CoA before making any component-specific statements.
No. This research product is not approved or supplied for inflammation, pain relief, immune support, tissue repair, wound healing, injury recovery, injection or human administration. It should be described only as a laboratory research product.
Not necessarily. BPC-157 + TB-500 is a named two-component blend. KLOW Peptide Blend 80mg should not be treated as the same product unless the CoA confirms the same components and amounts.
A peptide blend should be handled according to the product label, Certificate of Analysis, SDS, institutional procedure and validated research protocol. The full component list, component ratio and total concentration should be documented before use.
Blend names are often brand-style names rather than chemical identities. Without the CoA, it is not possible to confirm which peptides are present, how much of each peptide is present or what salt forms or counter-ions are included.
A Certificate of Analysis provides batch-level testing information. For a blend, it is especially important because researchers need to verify the ingredient list, component ratio, purity, salt forms and quality documentation before use in a research setting.
| Resource | Why It Is Useful |
| TGA guidance on unapproved peptide products | Important Australian regulatory context for unapproved peptide products, including products containing BPC-157, GHK-Cu and TB-500. |
| TGA warning on importing unapproved peptide products | Important Australian safety context for unapproved peptide products promoted online and concerns around poor labelling and unverifiable contents. |
KLOW Peptide Blend 80mg for qualified laboratory research only. Not for human or veterinary use.
Find research peptides, certificate documentation, guides and key product categories in one clean menu.